0.02%阿托品与角膜塑形术治疗近视对照研究。

PubMed ID
发表日期 2021年Feb月

原始出处 眼睛和隐形眼镜
Eye & contact lens
作者 Lyu  Yong  Ji  Na  Fu  Ai-Cun  Wang  Wei-Qun  Wei  Li  Qin  Jian  Zhao  Bing-Xin 

文献标题 0.02%阿托品与角膜塑形术治疗近视对照研究。
Comparison of Administration of 0.02% Atropine and Orthokeratology for Myopia Control.

文献摘要 OBJECTIVE

比较0.02%阿托品滴眼液与角膜塑形术控制近视儿童眼轴长度(AL)延长的效果。

METHODS

在这项历史对照研究中,纳入了247名近视儿童,他们服用0.02%阿托品(n=142)或接受早期研究的角膜塑形术(n=105,对照组)。在基线检查时以及治疗1年和2年后记录AL和其他基线参数的数据。

RESULTS

在治疗的第一年和第二年,AL的平均变化为0.30±0.21和0.28±0.02%阿托品组和0.16%阿托品组分别为0.20mm±0.20和0.20±角膜塑形术组分别为0.16mm。治疗2年后的轴向长度延长为0.58±0.35和0.36±0.02%阿托品组和角膜塑形术组分别为0.30mm(P=0.007)。多元回归分析显示,0.02%阿托品组的铝延伸明显快于角膜塑形术组(β=0.18,P=0.009)。在多元回归分析中,0.02%阿托品组较年轻和较短的基线铝与铝的快速延长有关(β年龄=-0.04,P=0.01;βAL=-0.17,P=0.03),而年龄越小,基线球面等效屈光不正(SER)越低,基线AL越短,角膜塑形术组的AL增加越大(β年龄=-0.03,P=0.04;βSER=0.06,P=0.03;β铝=-0.11,P=0.009)。与角膜塑形术组相比,0.02%阿托品组在更高的基线SER下铝延伸更快(P=0.04,交互试验)。

CONCLUSION

在本研究设计的范围内,角膜塑形术与0.02%阿托品治疗2年以上的高度近视儿童相比,似乎是一种更好的控制角膜延长的方法。


OBJECTIVE

To compare the efficacies of 0.02% atropine eye drops and orthokeratology to control axial length (AL) elongation in children with myopia.

METHODS

In this historical control study, 247 children with myopia whose administration of 0.02% atropine (n=142) or underwent orthokeratology from an earlier study (n=105, control group) were enrolled. Data on AL and other baseline parameters were recorded at baseline and after 1 and 2 years of treatment.

RESULTS

The mean changes in AL in the first and second years of treatment were 0.30±0.21 and 0.28±0.20 mm, respectively, in the 0.02% atropine group and 0.16±0.20 and 0.20±0.16 mm, respectively, in the orthokeratology group. Axial length elongations after 2 years of treatment were 0.58±0.35 and 0.36±0.30 mm (P=0.007) in the 0.02% atropine and orthokeratology groups, respectively. Multivariate regression analyses showed that the AL elongation was significantly faster in the 0.02% atropine group than in the orthokeratology group (β=0.18, P=0.009). In multivariate regression analyses, younger age and shorter baseline AL were associated with a rapid AL elongation in the 0.02% atropine group (βage=-0.04, P=0.01; βAL=-0.17, P=0.03), while younger age, lower baseline spherical equivalent refractive error (SER), and shorter baseline AL were associated with a greater increase in AL in the orthokeratology group (βage=-0.03, P=0.04; βSER=0.06, P=0.03; βAL=-0.11, P=0.009). Faster AL elongation was found in the 0.02% atropine group compared with the orthokeratology group at higher baseline SER (P=0.04, interaction test).

CONCLUSION

Within the limits of this study design, orthokeratology seems to be a better method for controlling AL elongation compared with administration of 0.02% atropine in children with higher myopia over a treatment period of 2 years.


获取全文 10.1097/ICL.0000000000000699